DeCure's autonomous Cardio AI scientist is researching a drug-repurposing hypothesis for dilated cardiomyopathy 1L — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleDilated cardiomyopathy 1L maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for dilated cardiomyopathy 1l is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
What the evidence adds up to
Dilated cardiomyopathy is defined by ventricular dilation and progressive systolic dysfunction, with causative mutations identified in more than 40 genes. The 2023 review notes that heart failure remains a leading cause of morbidity and mortality globally, and that in India a new case is diagnosed every 23 seconds. Even after diagnosis, only 25% to 40% of patients receive guideline-directed medical therapy. The heterogeneity in etiology and clinical presentation makes timely diagnosis and treatment challenging.
In a 2009 surgical study, 20 patients with dilated cardiomyopathy (10 ischemic, 10 idiopathic) received the Acorn CorCap cardiac support device. All survived the surgery, but four died during a mean follow-up of 32 months. After surgery, there was a significant reduction in cardiac dimensions, improved functional capacity, and improved quality of life. No significant differences were seen between patients with ischemic versus idiopathic disease. The authors called for further studies to identify optimal patient selection criteria, optimal timing of surgery, and to assess long-term effects.
The 2016 review describes that causative genetic mutations have been found in more than 40 genes encoding proteins from different cellular structures and pathways. The pathogenesis depends on the affected genes and the dislodged intracellular structures or mechanisms. No drug therapy is evaluated in these abstracts.
What is still missing is a clear understanding of which patients benefit from any given intervention, given the genetic and etiological heterogeneity. For the surgical device, long-term survival data and randomised comparisons are absent. For medical management, the gap between diagnosis and receipt of guideline-directed therapy remains large, and no trial design has yet addressed how to close it. Patient stratification by genetic subtype is not yet incorporated into treatment decisions.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Cardiovascular Medicine · 2016 · 15 citations
Genetic bases of dilated cardiomyopathy
AbstractCardiomyopathies represent a wide and heterogeneous group of diseases wherein a genetic cause has been consistently identified.Dilated cardiomyopathy (DCM) is characterized by ventricular dilation and progressive systolic dysfunction, and it is the most common form of cardiomyopathy.Causative genetic mutations have been identified in more than 40 genes encoding proteins belonging to different cellular structures and pathways.A great diversity of pathways has been implied in the pathogenesis of DCM, depending on the affected genes and on the dislodged intracellular structures or mechanisms.This review describes the major genes and focus on the pathophysiologic mechanisms of DCM, with a special consideration of the most recent discoveries in the field.
Midterm Results of Passive Containment Surgery Using the Acorn Cor Cap⢠Cardiac Support Device in Dilated Cardiomyopathy
AbstractBACKGROUND AND AIM: To evaluate the echocardiographic, functional, and quality of life improving effects of passive containment surgery using the CorCap cardiac support device (CSD; Acorn Cardiovascular Inc., St. Paul, MN, USA) in patients with dilated cardiomyopathy and to investigate the possible differences in ischemic versus idiopathic (i.e., normal angiograms) cardiomyopathy. METHODS: Twenty patients with dilated cardiomyopathy (10 with ischemic and 10 with idiopathic disease) were subjected to application of the cardiac support device, between June 2001 and October 2006. Preoperatively and at follow-up cardiac dimensions, cardiac function, functional capacity, and quality of life were evaluated. Follow-up is complete with a mean follow-up time of 32 +/- 5 months. RESULTS: All patients survived the surgery; four patients died during the follow-up time. Following surgery, there was a significant reduction in cardiac dimensions, improved functional capacity, and improved quality of life. No significant differences could be seen between patients with ischemic versus idiopathic disease. CONCLUSION: Application of the CSD is safe and simple in patients with dilated cardiomyopathy and without any apparent negative effects. Further studies are needed to identify optimal patient selection criteria as well as optimal timing of surgery and to assess the long-term effects of this treatment.
Heart failure journal of India · 2023 · 0 citations · open access
Management of non-ischemic dilated cardiomyopathy
AbstractHeart failure (HF) remains a leading cause of morbidity and mortality globally. For every 23 s, a new case of HF is diagnosed in India. Dilated cardiomyopathy is characterized by dilatation of the left ventricle or both ventricles with impaired function, which cannot be fully explained by abnormal loading conditions or coronary artery disease. The heterogeneity in etiology and clinical presentation of dilated cardiomyopathy makes timely diagnosis and treatment challenging. Even after diagnosis, only 25%–40% receive guideline-directed medical therapy.
AbstractDilated cardiomyopathy is defined by the presence of left ventricular dilatation and contractile dysfunction in the absence of abnormal loading conditions and severe coronary artery disease. Once dilated cardiomyopathy is discovered, a careful and detailed history with laboratory tests may reveal a potential toxic cause. In this article, we present the case of a patient with suspected toxic dilated cardiomyopathy, and then discuss the common causes and treatment of toxic dilated cardiomyopathy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
